

TEST CHANGE

Testosterone, Free (Adult Females, Children, or Individuals on Testosterone-Suppressing Hormone Therapy)

0081059, TESTOS FR

Specimen Requirements:

Patient Preparation: Collect between 6-10 a.m.

Collect: Serum separator tube or green (sodium or lithium heparin).

Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP [standard transport tube](#). ~~Standard Transport Tube~~. (Min: 0.8 mL)

Transport Temperature: Refrigerated.

Unacceptable Conditions: EDTA plasma.

Remarks:

Stability: After separation from cells: Ambient: 24 hours; Refrigerated: 1 week; Frozen: 6 months

Methodology: Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry/Electrochemiluminescent Immunoassay/Calculation

Performed: Sun-Sat

Reported: 1-~~5~~4 days

Note: Total ~~t~~estosterone and SHBG are measured and free testosterone is estimated from these measurements.

CPT Codes: 84402

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Free testosterone concentration is calculated using total testosterone (measured by mass spectrometry) and the binding constant of testosterone and sex hormone-binding globulin (SHBG).

For individuals on testosterone-suppressing hormone therapies (e.g., antiandrogens or estrogens), refer to cisgender female reference intervals. For a complete set of all established reference intervals, refer to ltd.aruplab.com/Tests/Pub/0081059.

~~This test was developed and its performance characteristics determined by ARUP Laboratories. It~~

~~has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.~~

Reference Interval:

| Test Number | Components | Reference Interval | | |
|-------------|---------------------------------|--------------------|---------------------------|----------------|
| | Testosterone, Free by Mass Spec | | | |
| | | Age | Male (pg/mL) | Female (pg/mL) |
| | | 1-6 years | Less than 0.6 | Less than 0.6 |
| | | 7-9 years | 0.1-0.9 | 0.6-1.8 |
| | | 10-11 | 0.1-6.3 | 0.1-3.5 |
| | | 12-13 | 0.5-98.0 | 0.9-6.8 |
| | | 14-15 | 3-138.0 | 1.2-7.5 |
| | | 16-17 | 38.0-173.0 | 1.2-9.9 |
| | | 18 years and older | 47-244 | Not Applicable |
| | | 18-30 | Not Applicable | 0.8-7.4 |
| | | 31-40 | Not Applicable | 1.3-9.2 |
| | | 41-51 | Not Applicable | 1.1-5.8 |
| | | Postmenopausal | Not Applicable | 0.6-3.8 |
| | | Tanner Stage I | Less than or equal to 3.7 | Less than 2.2 |
| | | Tanner Stage II | 0.3-21 | 0.4-4.5 |
| | | Tanner Stage III | 1.0-98.0 | 1.3-7.5 |
| | | Tanner Stage IV | 35.0-169.0 | 1.1-15.5 |
| | | Tanner Stage V | 41.0-239.0 | 0.8-9.2 |